Document:

Exhibit 4.6

RIGHTS AGREEMENT AMENDMENT NO. 2

This Amendment No. 2, dated as of January 3, 2008, to the Rights Agreement, dated as of September 5, 2002, as amended on October 23, 2006 (the “Rights Agreement”), is between Pharmos Corporation, a Nevada corporation (the “Company”), and American Stock Transfer & Trust Co. (the “Rights Agent”).

The Company and the Rights Agent have heretofore executed and entered into the Rights Agreement. Pursuant to Section 27 of the Rights Agreement, the Company and the Rights Agent may from time to time supplement or amend the Rights Agreement in accordance with the provisions of Section 27 thereof and the Company desires and directs the Rights Agent to so amend the Rights Agreement. All acts and things necessary to make this Amendment a valid agreement according to its terms have been done and performed, and the execution and delivery of this Amendment by the Company and the Rights Agent have been in all respects authorized by the Company and the Rights Agent. 

In consideration of the foregoing premises and mutual agreements set forth in the Rights Agreement and this Amendment, the parties hereto agree as follows:

1.            Section 1(a) of the Rights Agreement, which sets forth the definition of “Acquiring Person,” is hereby modified and amended to read in its entirety as follows:

(a)           “Acquiring Person” shall mean any Person (as such term is hereinafter defined) who or which, together with all Affiliates (as such term is hereinafter defined) and Associates (as such term is hereinafter defined) of such Person, shall be the Beneficial Owner (as such term is hereinafter defined) of 15% or more of the shares of Common Stock then outstanding or who was such a Beneficial Owner at any time after the date hereof, whether or not such Person continues to be the Beneficial Owner of 15% or more of the outstanding shares of Common Stock. Notwithstanding the foregoing, (i) in no event shall a Person who or which, together with all Affiliates and Associates of such Person, is the Beneficial Owner of less than 15% of the Company’s outstanding shares of Common Stock become an Acquiring Person solely as a
result of a reduction of the number of shares of outstanding Common Stock, including repurchases of outstanding shares of Common Stock by the Company, which reduction increases the percentage of outstanding shares of Common Stock beneficially owned by such Person (provided that any subsequent increase in the amount of Common Stock beneficially owned by such Person, together with all Affiliates and Associates of such Person, without the prior approval of the Company shall cause such Person to be an Acquiring Person); (ii) the term Acquiring Person shall not mean (A) the Company, (B) any subsidiary of the Company (as such term is hereinafter defined), (C) any employee benefit plan of the Company or any of its subsidiaries, or (D) any entity holding securities of the Company organized, appointed or established by the Company or any of its subsidiaries for or pursuant to the terms of any such plan; and (iii) no Person shall be deemed to be an Acquiring Person if (A) within five business
days after such Person would otherwise have become an Acquiring Person (but for the operation of this clause (iii)), such Person notifies the Board of Directors that such Person did so 

 

 

inadvertently and, within two business days after such notification, such Person is the Beneficial Owner of less than 15% of the outstanding shares of Common Stock, (B) by reason of such Person’s Beneficial Ownership of 15% or more of the outstanding shares of Common Stock on the date hereof if, prior to the Record Date, such Person notifies the Board of Directors that such Person is no longer the Beneficial Owner of 15% or more of the then outstanding shares of Common Stock or (C) the Board of Directors determines in good faith that a Person who would otherwise be an Acquiring Person, as defined pursuant to the foregoing provisions of this paragraph (a), has become such inadvertently, and such Person divests Beneficial Ownership as promptly as practicable of a sufficient number of shares of Common Stock so that such Person would no longer be an Acquiring Person, as defined pursuant to the foregoing
provisions of this paragraph (a). In addition, notwithstanding the foregoing, none of Vela Pharmaceuticals Inc., a Delaware corporation (“Vela”), or any Affiliate or Associate thereof, or any stockholder of Vela (including, without limitation, New Enterprise Associates, Venrock Associates and Robert Johnston) or Lloyd I. Miller, III, or their respective Affiliates or Associates, shall become an “Acquiring Person” as a result of (i) the approval, execution, delivery or performance of that certain Agreement and Plan of Merger dated as of March 14, 2006, as amended (and as the same may hereafter be amended from time to time, the “Merger Agreement”), by and among the Company, Vela and Vela Acquisition Corporation and Vela Acquisition No.2 Corporation, including the approval, execution, delivery or performance of any amendments thereto, (ii) the consummation of the Merger (as such term is defined in the Merger Agreement), (iii) the issuance of Common Stock
pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the Merger, (v) the consummation of any other transaction contemplated by the Merger Agreement, (vi) the approval, execution, delivery or performance of that certain Securities Purchase Agreement dated as of the date hereof (and as the same may hereafter be amended from time to time, the “Securities Purchase Agreement”) by and among the Company and the purchasers identified on the signature pages hereto, including the approval, execution, delivery or performance of any amendments thereto, (vii) the issuance of the Debentures, as defined in the Securities Purchase Agreement (the “Debentures”), (viii) the issuance of Common Stock upon conversion of the Debentures or any interest accrued thereon, (ix) the announcement of the transactions contemplated by the Securities Purchase Agreement, or (x) the consummation of any other transaction contemplated by the Securities Purchase Agreement.
Furthermore, none of Vela or any Affiliate or Associate thereof, or any stockholder of Vela (including without limitation New Enterprise Associates, Venrock Associates and Robert Johnston) or Lloyd I. Miller, III, shall become an “Acquiring Person” until such time as such Person, together with all Affiliates and Associates, is the Beneficial Owner of 20% or more of the shares of Common Stock then outstanding, including any shares of Common Stock issued pursuant to the Merger Agreement and held by such Person, together with all Affiliates and Associates.

2.            Section 1(i) of the Rights Agreement, which sets forth the definition of “Stock Acquisition Date,” is hereby amended by adding as the final sentence thereto the following: 

Notwithstanding anything in the Agreement to the contrary, no Stock Acquisition Date shall be deemed to have occurred in connection with or as a result of (i) the approval, execution, delivery or performance of the Merger Agreement, (ii) the consummation of the Merger, (iii) the issuance of Common Stock pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the 

 

2

 

 

Merger or (v) the consummation of any other transaction contemplated by the Merger Agreement, (vi) the approval, execution, delivery or performance of the Securities Purchase Agreement, (vii) the issuance of the Debentures, (viii) the issuance of Common Stock upon conversion of the Debentures or any interest accrued thereon, (ix) the announcement of the transactions contemplated by the Securities Purchase Agreement, or (x) the consummation of any other transaction contemplated by the Securities Purchase Agreement.

3.            Section 3(b) of the Rights Agreement is hereby amended by adding as the final sentence thereto the following:

Notwithstanding anything in this Agreement to the contrary, no Distribution Date shall be deemed to have occurred in connection with or as a result of (i) the approval, execution, delivery or performance of the Merger Agreement, (ii) the consummation of the Merger, (iii) the issuance of Common Stock pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the Merger or (v) the consummation of any other transaction contemplated by the Merger Agreement, (vi) the approval, execution, delivery or performance of the Securities Purchase Agreement, (vii) the issuance of the Debentures, (viii) the issuance of Common Stock upon conversion of the Debentures or any interest accrued thereon, (ix) the announcement of the transactions contemplated by the Securities Purchase Agreement, or (x) the consummation of any other transaction contemplated by the Securities Purchase Agreement.

 

4.            Section 11(a)(ii) of the Rights Agreement is hereby amended by adding as the final sentence thereto the following: 

Notwithstanding anything in this Agreement to the contrary, no event described in this Section 11(a)(ii) shall be deemed to have occurred solely as a result of (i) the approval, execution, delivery or performance of the Merger Agreement, (ii) the consummation of the Merger, (iii) the issuance of Common Stock pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the Merger or (v) the consummation of any other transaction contemplated by the Merger Agreement, (vi) the approval, execution, delivery or performance of the Securities Purchase Agreement, (vii) the issuance of the Debentures, (viii) the issuance of Common Stock upon conversion of the Debentures or any interest accrued thereon, (ix) the announcement of the transactions contemplated by the Securities Purchase Agreement, or (x) the consummation of any other transaction contemplated by the Securities
Purchase Agreement.

5.            Section 13(a) of the Rights Agreement is hereby amended by adding as the final sentence thereto the following: 

Notwithstanding anything in this Agreement to the contrary, none of the events described in clauses (x) through (z) of the first sentence of Section 13(a) shall be deemed to have occurred solely as a result of (i) the approval, execution, delivery or performance of the Merger Agreement, (ii) the consummation of the Merger, 

 

3

 

 

(iii) the issuance of Common Stock pursuant to the Merger Agreement, (iv) the announcement of the Merger Agreement or the Merger or (v) the consummation of any other transaction contemplated by the Merger Agreement, (vi) the approval, execution, delivery or performance of the Securities Purchase Agreement, (vii) the issuance of the Debentures, (viii) the issuance of Common Stock upon conversion of the Debentures or any interest accrued thereon, (ix) the announcement of the transactions contemplated by the Securities Purchase Agreement, or (x) the consummation of any other transaction contemplated by the Securities Purchase Agreement.

6.            Except as expressly amended hereby, the Rights Agreement remains in full force and effect in accordance with its terms. By executing this Amendment below, the Company certifies that this Amendment has been executed and delivered in compliance with the terms of Section 27 of the Rights Agreement. 

7.            This Amendment to the Rights Agreement shall be governed by and construed in accordance with the laws of the State of Nevada.

 

8.           This Amendment to the Rights Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed an original, and all such counterparts shall together constitute but one and the same instrument. 

9.            Except as expressly set forth herein, this Amendment to the Rights Agreement shall not by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 

10.          If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect.

11.          Capitalized terms used herein but not defined shall have the meanings given to them in the Rights Agreement.

 

*********************

 

4

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Rights Agreement to be duly executed as of the day and year first above written.

	
             
 	
            Pharmos Corporation
 
	
             
 	
            
 By: __________________________________
         Name:_____________________________
         Title:______________________________ 
 
	
             
 	
            
 American Stock Transfer & Trust Co.,

as Rights Agent
 
	
             
 	
            
 By: __________________________________
         Name:_____________________________
         Title:______________________________ 
 

 

 

 

5Exhibit 10.1

 

Pharmos Corporation

99 Wood Avenue South, Suite 311

Iselin, NJ 08830

 

January 3, 2008

 

Mony Ben Dor 

 

	
             
 	
            Re:
 	
            Pharmos Corporation (“Pharmos” or the “Company”)
 

 

Dear Mony:

 

This letter confirms the agreement between Pharmos Corporation (the “Company”) and you relating to your resignation, effective as of the date hereof, from the Board of Directors of the Company (the “Board”).  As we discussed, you are not resigning because of any disagreement on any matter relating to the Company’s operations, policies or practices.   

 

You have generously agreed to serve as a consultant to the Company following your resignation through the 2008 annual meeting of shareholders.  In connection therewith, you will make yourself available in person or by telephone, upon reasonable prior request, to the Board and its committees, as well as to members of senior management, on matters relating to general business development in your areas of expertise.  If we request you to appear periodically for meetings or the like, we will reimburse you for your reasonable expenses.  

 

In consideration for your services, we will issue to you 28,572 shares of common stock of the Company, the resale of which by you is covered by a current registration statement on Form S-8.  The shares are being issued to you in lieu of a cash consulting fee of $20,000, and the number of shares equals the amount of that fee, divided by $0.70, which is the conversion price of the convertible debentures being issued today by the Company to certain investors in a private placement transaction.  In addition, all stock options currently held by you will become fully vested as of the date hereof and will not expire until their respective expiration dates.  This letter shall be deemed to amend any option grant to which you are a party, and except as provided herein, such option grants will remain in full force and effect.

 

By this letter, we confirm to you that you will continue to be covered by the Company’s existing directors’ and officers’ liability insurance for your acts as a director of the Company through the date hereof, and further, that the Company’s By-Laws currently provide for indemnification of you in such capacity by the Company.

 

We have also agreed to provide you with advance copy of, and the ability to review, the required public disclosure of your resignation.

 

This agreement has been approved by the Board. 

 

Thank you for the important and significant contributions you have made to Pharmos during your tenure as a director. 

 

PHARMOS CORPORATION

 

By:________________________

	
             
 	
            S. Colin Neill,
 

Chief Financial Officer

AGREED AND ACCEPTED:

 

____________________ 

	
            Mony Ben Dor

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]